Novel advances in pancreatic cancer treatment

Expert Review of Anticancer Therapy

Volumn 8, Issue 6, 2008, Pages 993-1002

  Vulfovich, Michel ^a   Rocha Lima, Caio ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

Epithelial growth factor; Monoclonal antibodies; Pancreatic cancer; Targeted therapies; Vascular endothelial growth factor; VEGF

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IRINOTECAN; IXABEPILONE; IXEMPRA; LAPATINIB; MATUZUMAB; METALLOPROTEINASE INHIBITOR; MITOMYCIN; OXALIPLATIN; PLACEBO; PLATINUM COMPLEX; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEINASE INHIBITOR; SORAFENIB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTHRALGIA; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; FATIGUE; GRANULOCYTOPENIA; HUMAN; HYPERTENSION; HYPOKALEMIA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROSTATE CANCER; PROTEINURIA; REVIEW; SOLID TUMOR; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; DRUG DELIVERY SYSTEM; MORTALITY; PANCREAS TUMOR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG DELIVERY SYSTEMS; HUMANS; PANCREATIC NEOPLASMS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 47249118032     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.6.993     Document Type: Review

References (53)

1. Evans DB, Abbruzzese JL, Willett CG. Cancer of the Pancreas. In: Principles and Practice of Oncology (6tb Edition). DeVita VT, Hellman S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, Philadelphia, USA, 1126-1116 (2001).
2. Brand R. The diagnosis of pancreatic cancer. Cancer J. 7(4), 287-297 (2001).
3. Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer J. 78(3 Suppl.), 654-663 (1996).
4. Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 253(14), 2061-2067 (1985).
5. Ducreux M, Rougier P, Pignon JP et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann. Oncol. 13(8), 1185-1191 (2002).
6. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg. 230(6), 776-782 (1999).
7. Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15(6), 2403-2413 (1997).
8. Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J. Clin. Oncol. 25(18), 2607-2615 (2007).
9. Ychou M, Desseigne F, Guimbaud R et al. Randomized Phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma. (MPA). First results of the ACCORD 11 trial. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
10. Slebos RJ, Hoppin JA, Tolbert PE et al. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study. Cancer Epidemiol. Biomarkers Prev. 9(11), 1223-1232 (2000).
11. Brunner TB, Cengel KA, Hahn SM et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res. 65(18), 8433-8441 (2005).
12. Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed cherapy. Mol. Cancer Res. 3(7), 413-423 (2005).
13. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18(1), 4-25 (1997)
14. Baker CH, Solorzania CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 62(7), 1996-2003 (2002).
15. Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23(31), 8033-8040 (2005).
16. Kindler HL, Niedzwiecki D, Hollis D et al. A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. Presented at: 2007 GI ASCO Annual Meeting. Orlando, FL, USA, 19-21 January 2007.
17. Solorzano CC, Baker CH, Bruns CJ et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. 16(5), 359-370 (2001).
18. Kuo T, Fitzgerald A, Kaiser H, Sikic BI, Fisher GA. A Phase I study of the VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK 222584) and gemcitabine in patients with advanced pancreatic cancer. Presented at: 2006 GI ASCO. San Francisco, CA, USA, 26-28 January 2006.
19. Wallace A, Locker G, Nattam S et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a Phase II trial of the University of Chicago Phase II Consortium. Presented at: 2007 GI ASCO Annual Meeting. Orlando, FL, USA, 19-21 January 2007.
20. Spano J, Chodkiewicz C, Maurel J et al. A randomized Phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a Phase I component. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
21. Fukasawa M, Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin. Cancer Res. 11(1), 407-409 (2005).
22. Mulay M, Limentani SA, Carroll M. et al. Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination Phase I clinical trial of patients with advanced solid tumors. Presented at: 2006 ASCO Annual Meeting. Atlanta, GA, USA, 2-6 June 2006.
23. Dupont J, Rothenberg ML, Spriggs DR et al. Safety and pharmacokinetics of intravenous VEGF Trap in a Phase I clinical trial of patients with advanced solid tumors. Presented at: 2005 ASCO Annual Meeting. Orlando, FL, USA, 13-17 May 2005.
24. Kolibaba KS, Druker BJ. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1333(3), F217-F248 (1997).
25. Garcia-Echeverria C, Fabbro D, Therapeutically targeted anti-cancer agents: inhibitors of receptor tyrosine kinases. Mini. Rev. Med. Chem. 273-283 (2004).
26. Craven RJ, Lightfoot H, Cance WG. A decade of tyrosine kinases: from gene discovery to therapeutics. Surg. Oncol. 12(1), 39-49 (2003).
27. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin. Oncol. 29(5 Suppl. 14), 31-37 (2002).
28. Bruns CJ, Harbison MT, Davis DW et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. 6(5), 1936-4948 (2000).
29. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol. 22(13), 2610-2616 (2004).
30. Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in Patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. Presented at: 2007 ASCO Annual Meeting. Cbicago, IL, USA, 1-5 June 2007.
31. Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathway and apoptosis in human pancreatic adenocarcinoma. Mol. Cancer Ther. 1(10), 777-783 (2002).
32. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J. Clin. Oncol. 25(15), 1960-1966 (2007).
33. Ko AH, Dito E, Schillinger B et al. A Phase II study of bevacizumab (BEV) and erlotinib (ERL) in patients with gemcitabine (GEM)-refractory metastatic adenocarcinoma of the pancreas (PanCa). Presented at: 2007 GI ASCO Annual Meeting. Orlando, FL, USA, 19-21 January 2007.
34. Safran H, Iannitti D, Miner T et al. GW572016/gemcitabine and GW572016/gemcitabine/oxaliplatin, a two-stage, Phase I study for advanced pureticticobiliary cancer. Presented at: 2006 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2006.
35. Saxby AJ, Nielsen A, Scarlett CJ et al. Asessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuplody and survival. Am. J. Surg. Pathol. 29(9), 1125-1134 (2005).
36. Safran H, Iannitti D, Ramanathan R. et al. Herceptin and gemcitabine for metastatic pancreatic cancer that overexpress HER-2/neu. Cancer Invest. 22(5), 706-712 (2004).
37. Graeven U, Kremer B, Südhoff T et al. Phase I study of humanized IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody EMD72000 plus gemcitabine (Gem) in advanced pancreatic cancer. Br. J. Cancer 94(9), 1293-1299 (2006).
38. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22(4), 337-358 (2003).
39. Grant S, Dent P. Kinase inhibitors and cytotoxic drug resistance. Clin. Cancer Res. 10(7), 2205-2207 (2004).
40. Ito H, Gardner-Thorpe J, Zinnet MJ, Ashley SW, Whang EE. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134(2), 221-226 (2003).
41. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 10(7), 2307-2318 (2004).
42. Yezhelyev MV, Koehl G, Guba M et al. Inhibition of Src tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin. Cancer Res. 10(23), 8028-8036 (2004).
43. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7(5), 1429-1437 (2001).
44. Whitehead RP, McCoy S, Rivkin SE et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC#710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest. New Drugs. 24(6), 515-520 (2006).
45. Khong HT, Dreisbach I, Kindler HI. et al. A Phase II study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
46. Ueno H, Okusaka T, Furuse J et al. A multicenter Phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
47. Chiorean EG, Dragovich T, Hamm J et al. Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
48. Cusack JC, Liu R, Xia L, Neuteboom S, Palladino M. Salinosporamide A, a novel orally active proteasome inhibitor NPI-0052 enhances tumoricidal response to multidrug chemo- and molecular therapy regimens in a pancreatic cancer xenograft model. Presented at: 2006 GI ASCO Annual Meeting. San Francisco, CA, USA, 19-21 January 2006.
49. McGardand LP, Mulcahy MF, Rademaker A et al. Phase I/II study of imatinib mesylate and gemcitabine for advanced pancreas cancer. Presented at: 2006 GI ASCO Annual Meeting. San Francisco, CA, USA, 19-21 January 2006.
50. Nugent FW, Cunningham C, Barve MA et al. Phase II study of talabostat/gemcitabine in Stage IV pancreatic cancer. Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
51. Evans T, Ramanathan RK, Yazji S et al. Final results from cohort 1 of a Phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). Presented at: 2007 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2007.
52. Ferrari V, Valcamonico F, Amoroso V et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a.Phase II trial. Cancer Chemother. Pharmacol. 57(2), 185-190 (2006).
53. Cox JV, Cartwright T, Neubauer M et al. A Phase II study of gemcitabine plus zoledronic acid in subjects with Stage IV pancreatic cancer. Presented at: 2006 ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2006.